Perceptic Technologies Limited

Based in the United Kingdom, Perceptic Technologies Limited, dba Perceptic, operates as a B2B artificial intelligence software developer. The company provides AI platforms, data integration tools, and decision‑support systems for pharmaceutical research. Based in London, United Kingdom and founded in 2024, Perceptic Technologies Limited provides artificial intelligence software solutions for the pharmaceutical and biotechnology sectors. The company focuses on developing an AI operating system that streamlines drug discovery and development workflows.

It was founded by Tilman Flock, Zaki Trache, and Martin Copes, with Tilman Flock serving as CEO. As of June 2026, the company is led by its CEO, Tilman Flock. In May 2026, the company raised USD 12 million in seed funding to support product development and expansion initiatives. The company works with enterprise pharmaceutical and biotechnology clients to provide artificial intelligence software for drug development lifecycle management.

Its platform integrates scientific evidence, clinical data, and research workflows into a unified intelligence layer that supports asset scouting, scientific evaluation, and clinical data analysis. The company offers configurable AI modules that replicate scientific reasoning, enabling hypothesis testing, data synthesis, and decision tracking. Supported by engineers, data scientists, and domain experts, the platform enhances collaboration across research teams and integrates with existing biopharma systems, databases, and modeling tools for seamless adoption. The company’s revenue is generated by offering its artificial intelligence platform to pharmaceutical, biotechnology, and research organizations through subscription‑based software agreements.

Clients typically engage via enterprise contracts that provide ongoing access to data integration, analytics, and decision‑support tools. These agreements may include tiered pricing based on usage, scale, and customization requirements, enabling organizations to integrate the platform into research workflows while benefiting from continuous updates, support services, and enhanced analytical capabilities. The company will use the May 2026, funding to scale engineering capabilities, expand its customer base, and grow its market presence. It aims to enhance platform features, introduce new functionalities, and expand into additional geographic markets, including North America and Asia, while strengthening its presence among global pharmaceutical and biotechnology clients.